Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis

Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China

NCT02668640 ·Status: COMPLETED

A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China

NCT01464021 ·Status: TERMINATED

Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab

NCT00650390 ·Status: APPROVED_FOR_MARKETING

Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.

NCT01561313 ·Status: COMPLETED ·Phase: PHASE2

Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

NCT00235872 ·Status: COMPLETED ·Phase: PHASE3

A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab

NCT01502423 ·Status: COMPLETED ·Phase: PHASE2

Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases

NCT03339089 ·Status: COMPLETED

A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)

NCT02955212 ·Status: COMPLETED ·Phase: PHASE3

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

NCT00646178 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.

NCT00195702 ·Status: COMPLETED ·Phase: PHASE3

Investigation of Immunological and Pharmacological Factors for Response to Adalimumab in Rheumatoid Arthritis

NCT03110094 ·Status: COMPLETED ·Phase: NA

A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis

NCT00233571 ·Status: COMPLETED ·Phase: PHASE3

Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis

NCT00649545 ·Status: APPROVED_FOR_MARKETING

Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate

NCT02786563 ·Status: WITHDRAWN

Tolerance, Pharmacokinetics and Preliminary Efficacy of T0001 in RA (Rheumatoid Arthritis)

NCT02481180 ·Status: TERMINATED ·Phase: PHASE1

Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

NCT00646386 ·Status: COMPLETED ·Phase: PHASE2

Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents

NCT01783730 ·Status: COMPLETED

Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis

NCT00690573 ·Status: COMPLETED ·Phase: PHASE3

Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate

NCT00235859 ·Status: COMPLETED ·Phase: PHASE3

Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab

NCT01752855 ·Status: COMPLETED ·Phase: PHASE2

Special Investigation of Humira® (Adalimumab) on Long-term Treatment in Patients With Rheumatoid Arthritis

NCT01163318 ·Status: COMPLETED

A Study of the Pharmacokinetics and Safety of SM03 in Patients With Rheumatoid Arthritis

NCT04704492 ·Status: COMPLETED ·Phase: PHASE1

Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

NCT00235833 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

NCT01077258 ·Status: COMPLETED

Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously

NCT02805010 ·Status: UNKNOWN ·Phase: PHASE1